Skip to content

Puerarin tablets in the treatment of endometriosis: a prospective, randomized, double-blind, multicenter clinical study

Puerarin tablets in the treatment of endometriosis: a prospective, randomized, double-blind, multicenter clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036735
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Interventions

Sponsors

The First Affiliated Hospital of the Navy Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) According to the EM pathology diagnosis standard, blood stasis of TCM diagnostic criteria and exclusion criteria included in patients with EM; (2) Between the ages of 18 and 45 years; (3) Boluntary participation in this study and the signing of the informed consent; (4) People who have not been treated with western medicine or had been treated with western medicine but have been stopped for 3 months.

Exclusion criteria

Exclusion criteria: (1) Adenomyosis of the uterus; (2) Complicated internal medical diseases of heart, lung, liver, kidney, hematopoiesis and nervous system; (3) Pregnant and lactation women.

Design outcomes

Primary

MeasureTime frame
response rate of EAPP;

Secondary

MeasureTime frame
COX - menstruation symptom scores;Ovarian endometriosis cyst diameter;Uterine bleeding;TCM syndrome score;EHP-5;

Countries

China

Contacts

Public ContactYu Chaoqin

The First Affiliated Hospital of the Navy Military Medical University

chqyu81@163.com+86 13818390984

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026